EC grants marketing authorisation for Raxone in Leber’s Hereditary Optic Neuropathy
Posted: 9 September 2015 |
Raxone is the first approved treatment for Leber’s Hereditary Optic Neuropathy, and for a mitochondrial disease, in the EU…
The European Commission has granted marketing authorisation for Santhera’s Raxone as the first approved medicine available in the EU for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON).
This rare condition is an inherited mitochondrial disease which if untreated usually leads to rapid, profound and permanent blindness in otherwise healthy patients.
“Our data demonstrate that Raxone treatment can prevent patients from further vision loss and can promote clinically relevant recovery of vision,” said Thomas Meier, PhD, Chief Executive Officer of Santhera. “The European approval of Raxone as an efficacious treatment for LHON and as the first approved medication for a mitochondrial disease, is a major milestone for Santhera as it marks our transition to a pharmaceutical company with a product on the market.”
Raxone a ‘major breakthrough’ in mitochondrial disease treatment
“Raxone represents a major breakthrough in mitochondrial disease treatment, and its approval paves the way for patients with LHON to be treated and to achieve a meaningful improvement of their visual acuity,” said Thomas Klopstock, MD, Professor for Neurology at the University of Munich, LHON researcher and coordinator of the German network for mitochondrial disorders, mitoNET. “LHON is a particularly devastating condition because sufferers, who are otherwise healthy and often young, rapidly become bilaterally blind within a few months. Most will remain permanently blind if untreated.”
Raxone is an oral medication authorised at a daily dose of 900 mg (given as 2 tablets three times a day with food), for the treatment of visual impairment in adolescent and adult patients with LHON. Efficacy data come from Santhera’s randomised, placebo-controlled RHODOS trial and from the open label Expanded Access Programme, which together have demonstrated that vision loss can be mitigated or reversed in patients treated with Raxone.